BCL2 has already been proposed as a therapeutic target as its pharmacological inhibition stops ASCL1‐dependent tumor growth (Shoemaker et al, 2008; Augustyn et al, 2014; Gay et al, 2021). This evidence concerns the gene BCL2 and neoplasm.